|Bid||1.5600 x 3100|
|Ask||1.6900 x 1300|
|Day's Range||1.4801 - 1.6900|
|52 Week Range||0.9550 - 3.9900|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for BIAF
SAN ANTONIO,, November 30, 2023--CMS has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.
SAN ANTONIO, November 28, 2023--bioAffinity Technologies VP of Research David Elzi, Ph.D., named to post with the American Society for Cell Biology
SAN ANTONIO, Texas, November 15, 2023--bioAffinity Technologies today launched a campaign in partnership with the ACS to increase lung cancer screening in Texas.